Breaking Down Barriers: Can LC–MS Revolutionize the Quantitation of Drug Product Impurities?

Here is some of the most popular content posted on LCGC International this week.

Learn how effective non-targeted analysis in soil samples is enabled through high resolution accurate mass in combination with intelligent data processing from Compound Discoverer.

Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.

Hear from Associate Professor Douglas Walker at Emory University on how GC Orbitrap MS has advanced their capability in exposomics research.

Explore the interior of the Orbitrap Exploris GC 240 to discover its key components and the experiments that can be conducted to enhance analytical flexibility.